These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28111724)

  • 1. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).
    Mendes RE; Sader HS; Smart JI; Castanheira M; Flamm RK
    Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1013-1017. PubMed ID: 28111724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
    Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019).
    Sader HS; Carvalhaes CG; Mendes RE
    Int J Infect Dis; 2021 Jan; 102():524-528. PubMed ID: 33207274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR; Smith CJ; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Pawlak J; Johnson LB
    J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
    Jones RN; Flamm RK; Castanheira M; Sader HS; Smart JI; Mendes RE
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):184-187. PubMed ID: 28377166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
    Ruggero MA; Peaper DR; Topal JE
    Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE; Moet GJ; Janechek MJ; Jones RN
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):93-7. PubMed ID: 21851873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.